intellectual property

Drug inventor report profiles individuals, US states, and countries leading pharmaceutical innovation

August 16, 2010

A new report from DrugPatentWatch.com profiles the leading researchers, US states, and countries responsible for drugs approved over the past ten years. The report features: Top Inventors Which inventors were granted the most patents? Patents per Inventor The patents awarded to each inventor Approved Drugs per Inventor The approved drugs protected by each inventor’s patents [...]

Read the full article →

Patent Analysis: A Tool for Making Strategic Business Decisions

June 14, 2010

This is a student paper from the 2010 final projects in the NIH Foundation for Advanced Education in the Sciences’ TECH 366 — Biotechnology Management. The students were asked to tell a story based on the course lectures, and to expand with general lessons on biotechnology company management. Patent Analysis: A Tool for Making Strategic [...]

Read the full article →

India, Intellectual Property and Biotechnology Industry

December 3, 2009

This is a guest post from BiotechBlog reader Viren Konde. Do you have a response to Viren’s post? If so, you may respond in the comments section below. The recent editorial on “Intellectual property and biotechnology innovation: To protect or not protect” by Dr Yali Friedman, Managing Editor of the Journal of Commercial Biotechnology was [...]

Read the full article →

Biologic data exclusivity: The arguments for and against it

October 26, 2009

With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that will be published in the upcoming issue of the Journal of Commercial Biotechnology: Why data exclusivity is the new patent protection Peter J Pitts, Center for medicine in the public interest Follow-on biologic drug competition [...]

Read the full article →

The changing roles of CRO

May 27, 2009

This is a student paper from the 2009 final projects in the NIH Foundation for Advanced Education in the Sciences’ TECH 366 — Biotechnology Management. The students were asked to tell a story based on the course lectures, and to expand with general lessons on biotechnology company management. The changing roles of CRO Alex Bao [...]

Read the full article →

Assessing India’s Innovation Climate

April 23, 2009

In 2005 India mostly strengthened their patent laws to meet international norms, with the distinct requirement that new drug products must “differ significantly in properties with regard to efficacy.” This requirement for a significant improvement in efficacy only applies to drugs — not to other patentable inventions like pens, car engines, etc., and is of [...]

Read the full article →

Drug Development – Balancing National and Commercial Needs

February 20, 2009

I’ll be giving a talk at the Kogod School of Business on Tuesday February 24th on “Drug Development – Balancing National and Commercial Needs”. The basis of the talk is that countries need access to medicines, foreign currency, and tax revenues, while drug developers need profits (or else they will cease to exist). I’ll be [...]

Read the full article →

Introducing Biotech-U: Web-based courses on biotechnology

January 14, 2009

After months of effort, I’m pleased to announce the launch of Biotech-U, a biotechnology education resource featuring web-based lessons on biotechnology business, law, IP, politics, regulations, and science. Biotech-U is based on Building Biotechnology, the leading text used in business-of-biotechnology courses. The online-learning structure is designed to meet the needs of busy professionals who seek [...]

Read the full article →

Intellectual Property Theft on the Rise

October 14, 2008

Guest content from John Avellanet, managing director and principal of Cerulean Associates: Intellectual Property Theft on the Rise By John Avellanet, Managing Director and Principal of Cerulean Associates LLC Reprinted with permission from SMARTERCOMPLIANCE™ 2(9): p 1-2 (September 2008) Nine out of ten companies do not have appropriate policies and controls in place to stop [...]

Read the full article →

Commercializing biotechnology in China

September 17, 2008

I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience on doing business with and in China: Tell me about HUYA and what makes the company unique? HUYA Bioscience International has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and [...]

Read the full article →

← Previous Entries